Monte Carlo Resampling Validates Use of Bone Mineral Density Change as Surrogate to Replace Fracture in Future Randomized Trials of Osteoporosis Treatments: Results From SABER
{{output}}
We have proposed 24-mo between-treatment difference (active-placebo) in mean percent change in total hip bone mineral density (%THBMD) be used to evaluate whether a drug will likely reduce fracture risk, such that a mean %THBMD change greater than the surrogat... ...
